1/48
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced |
---|
No study sessions yet.
Can you use SOF/VEL (Epclusa) in decompensated cirrhosis?
Yes
Can you use G/P (Mavyret) in decompensated cirrhosis?
No
Can you use SOF/VEL/VOX (Vosevi) in decompensated cirrhosis?
No
Can you use EBR/GZR in decompensated cirrhosis?
No
Can you use LDV/SOF (Harvoni) in decompensated cirrhosis?
Yes
What are the HCV Pre-treatment labs?
Confirm HCV infections
HIV status
HBV status
Assess renal function
Assess INR
Check hepatic function panel (AST, ALT)
GT for LDV/SOF
1,4-6
GT for EBR/GZR
1,4
GT for SOD/VEL
1-6
GT for SOF/VEL/VOX
1-6
GT for G/P
1-6
Is LDV/SOF used in CKD, ESRD?
Yes
Is EBR/GZR used in CKD, ESRD?
Yes
Is SOF/VEL used in CKD, ESRD?
Yes
Is G/P used in CKD, ESRD?
Yes
Daily DAA pill burden of LDV/SOF
1
Daily DAA pill burden of EBR/GZR
1
Daily DAA pill burden of SOF/VEL
1
Daily DAA pill burden of SOF/VEL/VOX
1
Daily DAA pill burden of G/P
3
Do you take with or without food: LDV/SOF
+-
Do you take with or without food: EBR/GZR
+-
Do you take with or without food: SOF/VEL
+-
Do you take with or without food: SOF/VEL/VOX
With
Do you take with or without food: G/P
With
Length of therapy of LDV/SOF
8-12 weeks
Length of therapy of EBR/GZR
12-16 weeks
Length of therapy of SOF/VEL
12 weeks
Length of therapy of SOF/VEL/VOX
12 weeks
Length of therapy of G/P
8 weeks
ADRs of LDV/SOF
fatigue, HA
ADRs of EBR/GZR
fatigue, HA, nausea
ADRs of SOF/VEL
fatigue, HA
ADRs of SOL/VEL/VOX
fatigue, HA, nausea, diarrhea
ADRs of G/P
Fatigue, HA
DDIs for LDV
Needs acidic stomach for absorption
Caution with antacids, H2RAs, PPI
DDIs for SOF
Substrate of P-gp and BCRP
Drug interactions possible with P-gp inhibitors/inducers
DDIs for EBR
Metabolized by CYP3A4
Substrate of P-gp
DDIs of GZR
Weak CYP3A4 inhibitor
Also CYP3A4 and P-gp substrate
DDIs VEL
Needs acidic environment for absorption
Interaction risk with acid-reducing agents
Inhibits P-gp, OATp1B1/3 (weak), BCRP (moderate)
Substrate of OATP1B1/3
Metabolized by CYP3A4, CYP2B6, CYP2C8
DDIs for VOX
Substrate of OATP1B1/3
Metabolized by CYP3A4, CYP1A2, CYP2C8
DDIs for G/P
Inhibit P-gp, BCRP, OATP1B1/3
Weakly inhibit CYP3A4, CYP1A2, UGT1A1
Broad potential for drug-drug interactions
DAA Class of LDV
NS5A
DAA Class of SOF
NS5B
DAA Class of EBR
NS5A
DAA Class of GZR
PI
DAA Class of VEL
NS5A
DAA Class of VOX
PI
DAA Class of G/P
PI/NS5A